FEMY News and Press, Femasys Inc. From 07/28/23

2023-07-28 06:00:00 ET 3 Tips for Investing in Penny Stocks in the AI Industry The allure of the artificial intelligence (AI) industry is undeniable. As AI applications continue to redefine sectors from healthcare to finance, the growth potential is vast. Investors aiming to capitalize ...

ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite of product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced ...

2023-06-26 12:31:58 ET Femasys ( NASDAQ: FEMY ) shares jumped 21% midday Monday following news that the US Food and Drug Administration has approved its investigational device exemption application to begin clinical trials for its birth control product FemBloc. The product is in...

- Pivotal clinical trial to begin in the third quarter of 2023 - ATLANTA, June 26, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-offic...

-- Keith Kendall former President, COO and CFO of drug delivery company, Aquestive Therapeutics and Alistair Milnes COO of biotechnology company, Bicycle Therapeutics both join Femasys’ Board of Directors -- ATLANTA, June 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY...

ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsic...

-- FemCath ® is the first intrauterine catheter that allows for selective evaluation of a fallopian tube with natural saline and air contrast -- -- FemCath is used in conjunction with Femasys’ FemVue ® product as a baseline diagnostic test for infert...

2023-05-12 10:01:42 ET Femasys press release ( NASDAQ: FEMY ): Q1 GAAP EPS of -$0.25. Revenue of $0.29M (-9.4% Y/Y). For further details see: Femasys GAAP EPS of -$0.25, revenue of $0.29M

-Received regulatory approval for both FemaSeed ® and FemCerv ® products from Health Canada- ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of produc...

ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Companyȁ...